检索结果-南通市图书馆

World Journal of Gastroenterology 2016年第11期22卷 3127-3149页

作者： Alan Alper Sag Fatih Selcukbiricik Nil Molinas Mandel Division of Interventional Radiology Department of RadiologyKoc University School of Medicine Division of medical oncology Department of Internal MedicineKoc University School of Medicine

Colorectal cancer metastasizes predictably, with liver predominance in most cases. Because liver involvement has been shown to be a major determinant of survival in this population, liver-directed therapies are increasingly considered even in cases where there is(limited) extrahepatic disease. Unfortunately, these patients carry a known risk of recurrence in the liver regardless of initial therapy choice. Therefore, there is a demand for minimally invasive, non-surgical, personalized cancer treatments to preserve quality of life in the induction, consolidation, and maintenance phases of cancer therapy. This report aims to review evidence-based conceptual, pharmacological, and technological paradigm shifts in parenteral and percutaneous treatment strategies as well as forthcoming evidence regarding next-generation systemic, locoregional, and local treatment approaches for this patient population.

关键词： Colonic neoplasms Rectal neoplasms Neoplasm metastasis Antineoplastic agents FOLFOX protocol Irinotecan 5-flurouracil and leucovorin protocol Radiofrequency ablation Microwave ablation Chemoembolization Therapeutic Immunotherapy

Management of Malignants Gliomas: About 20 Cases Treated in the medical oncology Department of Fattouma Bourguiba University Hospital-Monastir

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Cancer Therapy 2021年第8期12卷 478-485页

作者： Hiba Sboui Amira Daldoul Nader Slema Amal Chamsi Sonia Zaied medical oncology Department Fattouma Bourguiba Hospital Monastir Tunisia

Introduction: Malignant gliomas refer to grade III or IV brain tumors defined according to the World Health Organization (WHO) classification. They are a heterogeneous group of pathologies and represent a serious health problem by their frequency, severity and treatment difficulties. The prognosis of malignant gliomas remains poor despite all the medical advances. Materials and Methods: It is a retrospective study included 20 cases of malignant glial tumors treated at the medical oncology department, Fattouma Bourguiba hospital in Monastir between 2012 and 2016, according to the STUPP protocol. Results: These were 12 men and 8 women with a median age of 43. Clinical signs were not very specific, dominated by intracranial hypertension and deficit signs. Imagery referred to the diagnosis of malignant gliomas in 1st intention. Surgery consisted of a macroscopically complete exeresis in (15%) cases, a partial exeresis in (50%), the rest of the patients had a stereotactic biopsy. Histology found GBM in 16 patients (80%), 2 cases of Grade III anaplastic astrocytoma (10%), 1 case of anaplastic oligodendroglioma (5%), and 1 case of Grade III anaplastic eppendymoma (5%). Most of our patients received concurrent radio-chemotherapy and adjuvant TMZ chemotherapy was administered in 15 patients,

关键词： Malignant Gliomas Surgery Radiotherapy Chemotherapy Prognosis

Non-Clear Cell Renal Carcinomas: About 23 Cases Experience of the medical oncology Department of the Hassan II Hospital in Fez, Morocco

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Open Journal of Nephrology 2021年第1期11卷 34-42页

作者： Lamyae Nouiakh Karima Oualla Imane Ouafki Soumia Berrad Hayat Erraichi Lamiae Amaadour Zineb Benbrahim Samia Arifi Nawfel Mellas Department of medical oncology Hassan II University Hospital Fes Morocco

Background: Non-clear cell renal cell carcinomas represent a very rare and heterogeneous variety of kidney cancer. The aim of this study is to describe the main epidemiological, clinical, paraclinical, histological and therapeutic characteristics of these cancers. Methods: A descriptive retrospective study was conducted in the medical oncology Department of the Hassan II Hospital in Fez, collecting 23 patients with these tumors during the period from January 2008 to January 2020. The statistical analysis is made by the SPSS software version 23. Survival was calculated by the Kaplan-Meier method. Results: The average age of the patients was 57.4 years. The sex ratio M/F was 1.3. The main risk factor was smoking (n = 10). The most common symptom was low back pain (n = 23). 17 patients were metastatic, while 6 patients had localized disease. The most common histological type was papillary carcinoma (n = 12). Patients with localized disease have undergone an extended total nephrectomy. After a median follow-up of 145 months, the median of recurrence-free survival was 48 months and that of overall survival was 150 months. In a metastatic situation, 16 patients had received systemic treatment, of which 13 patients had received sunitinib, 2 patients pazaopanib and only one patient received everolimus. After a median follow-up of 20 months, the median of progression-free survival was 5 months and that of overall survival was 9 months. Conclusion: At the present time, there is no therapeutic standard for the management of patients with these tumors. Surgery for people with localized or locally advanced disease remains the initial and most important approach. For patients with advanced disease, a clinical trial should be considered.

关键词： Kidney Non-Clear Cell Carcinoma Targeted Therapy

Lung cancer management during the COVID-19 pandemic:experience of a medical oncology unit at a tertiary hospital in Singapore

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Cancer Metastasis and Treatment 2020年第1期6卷 707-717页

作者： Elise KY Vong Puey-Ling Chia Alex Y.Chang Department of medical oncology Tan Tock Seng HospitalSingapore Lee Kong Chian School of Medicine Singapore Johns Hopkins University School of Medicine BaltimoreMD 21836USA

Coronavirus disease 2019(COVID-19),caused by the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),was declared a pandemic by the World Health Organisation(WHO)on 11 March *** pandemic has had profound effects on healthcare systems across the world,and also poses unique challenges for oncology *** saw its first imported case of COVID-19 on 23 January 2020,and there has since been 52,000 confirmed cases and 27 deaths as of early August 2020 *** have a special duty to our patients to ensure patient safety and provide optimum care without undue disruption which may compromise long-term cancer-specific *** herein examine the impact that the COVID-19 pandemic has had on our clinical services,and share our experience with regards to manpower reconfiguration,infection control measures,diagnostic evaluation of patients with suspected COVID-19,oncological management of lung cancer patients,as well as changes in the education and training of juniors,from our unique position as a medical oncology department in Tan Tock Seng Hospital,a tertiary hospital affiliated with the National Centre of Infectious Diseases in Singapore.

关键词： COVID-19 lung cancer thoracic cancer

Comparison of Clinicopathological and Survival Features of Right and Left Colon Cancers: Experience of the medical oncology Department of Fez

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Cancer Therapy 2023年第6期14卷 291-298页

作者： Soukaina El Anssari Youssef Elhaitmy Lamiae Amaadour Karima Oualla Zineb Benbrahim Samia Arifi Nawfel Mellas Department of medical oncology University Hospital Center Hassan II City of Fez Morocco

Right-sided colon cancers (RCC) and left-sided colon cancers (LCC) have different epidemiological, physiological, pathological, genetic, and clinical characteristics, which result in differences in the course, prognosis, and outcome of disease. The objective of our study is to compare right-sided colon cancers and left-sided colon cancers regarding clinicopathological and survival characteristics. This is a retrospective study of 664 patients with colon cancer treated at the medical oncology department of Fez over a period from December 2009 to September 2020. Rectosigmoid, descending colon, and splenic flexure tumors were considered left-sided colon cancers, whereas ascending colon tumors were considered right-sided colon cancers. The Kaplan Meier method was used to estimate median survival. The study included 664 patients (female, 47%) having colon cancer with a median age of 60 years (23 - 83). Of the patients, 78.5% (n = 519) had LCC and 19.36 % (n = 128) had RCC. The rate of patients aged ≥ 65 years and the rate of patients with a family history of colon cancer was higher in the LCC patients. The proportion of poorly differentiated adenocarcinomas represented 3%, of which 63% had cancer of the right colon. There was a significantly higher proportion of higher T stage (T3-4: 62% vs 38%) in right sided tumors as compared to left sided tumors. The rate of metastatic patients was 64.1% in the RCC group and 43% in the LCC group. The median follow-up period was 14 months in the RCC group and 19 months in the LCC group with higher median overall survival in the LCC group (32 vs 21 months). We found histopathological differences between right and left sided colon cancer. Tumors on the right colon were found to be more aggressive, as expressed by poorer differentiation, higher T stage associated with a median overall survival better in left colon cancer.

关键词： Right-Sided Colon Cancers (RCC) Left-Sided Colon Cancers (LCC) Prognosis Survival

medical oncology management of advanced hepatocellular carcinoma 2019: a reality check

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Frontiers of Medicine 2020年第3期14卷 273-283页

作者： Amy Lee Fa-Chyi Lee Department of Biology University of California San DiegoSan DiegoCA 92093USA Division of Hematology/oncology Department of Internal MedicineUniversity of California IrvineOrangeCA 92868USA

In terms of global cancer-related deaths,hepatocellular carcinoma (HCC) has the fourth highest mortality *** until 2017,treatment of advanced HCC was largely limited to sorafenib,an oral tyrosine kinase inhibitor,with little to no success in the development of alternative treatment ***,in the past two years,there has been an unprecedented increase in both the number and type of treatment options available for *** of 2019,the US FDA has approved four oral tyrosine kinase inhibitors,two immune checkpoint inhibitors,and one anti-angiogenesis antibody for the treatment of *** with this new variety,systemic treatment of advanced HCC remains largely unsatisfactory,and the median survival rate stands at approximately one *** expected breakthrough of using immune checkpoint inhibitors in advanced HCC did not materialize in *** use of immune checkpoint inhibitors in conjunction with oral tyrosine kinase inhibitors or antiangiogenesis medications is the current clinical research trend,the results of which are eagerly *** limited progress in survival,HCC research is currently experiencing a period of growth and innovation,and there is hope for significant advances in the treatment of advanced HCC as the field continues to develop.

关键词： hepatocellular carcinoma tyrosine kinase inhibitor check point inhibitor anti-angiogenesis

Impact of the COVID-19 Pandemic on Cancer Patients: Experience of the medical oncology department of CHU HASSAN II Fez.

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Cancer Therapy 2024年第3期15卷 83-91页

作者： Khadija Hinaje Oumaima Talbi Lamiae Amaadour Karima Oualla Zineb Benbrahim Samia Arifi Nawfel Mellas Department of medical oncology Hassan II University Hospital University Sidi Mohamed Ben Abdellah Fez Morocco

Introduction: In December 2019, COVID 19 spread worldwide, but did not officially start in MOROCCO until March 02, 2020. Since then, this pandemic has significantly impacted the health status of patients in general and cancer patients in particular. The main objective of our study is to evaluate the prognosis of patients treated for cancer and infected with COVID-19. Material and method: A descriptive study with prospective collection was carried out at the medical oncology department of CHU Hassan II in FEZ over a period of two years, from March 2020 to March 2022. Data was carried out on the software SPSS. Results: One hundred cancer patients tested positive for COVID-19 infection and were collected within our department. The average age was 56 years [22-91]. The sex ratio was 1.2. Patients with breast cancer were the most affected by this infection (34%). The clinical symptomatology was dominated by the respiratory syndrome (45%).The diagnosis was made through thoracic CT scan in 62% of cases. 76% of patients were in a metastatic stage. 96% of patients were undergoing oncological treatment. For symptomatique patients, the standard treatment approach involved using antibiotics in 76% of cases. Evolution was marked by recovery in 79% of patients, with a death rate of 12% in this cancer patient population. Conclusion: COVID-19 infection is particularly severe in cancer patients. Mortality among these patients remains high and is associated with overall patient characteristics. However, anticancer treatments have not shown deleterious effects on the course of COVID-19.

关键词： COVID-19 Cancer. SARS-CoV-2

Insights on liver-directed surgical innovations, targeted therapies, and immunotherapy for biliary tract cancer: navigating the new European Society for medical oncology (ESMO) Clinical Practice Guidelines

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Hepatobiliary Surgery and Nutrition 2024年第3期13卷 516-519页

作者： Ajay V.Maker Division of Surgical oncology Department of SurgeryUniversity of CaliforniaSan FranciscoCAUSA

Cancers of the bile duct,including gallbladder cancer,extrahepatic cholangiocarcinoma,hilar and intrahepatic cholangiocarcinoma,present a significant treatment *** by their notorious difficulty to diagnose or biopsy,intricate anatomical locations and diverse clinical presentations,these malignancies collectively contribute to a significant burden on global *** epidemiology of bile duct cancers reveals worldwide variations in incidence,prevalence,and mortality rates,emphasizing the need for a nuanced understanding of each subtype and the local environmental *** in early diagnosis further compound the complexity of managing these cancers,often leading to advanced stage at the time of detection and treatment *** remains the cornerstone of curative-intent treatment of bile duct cancers,yet the rate of recurrence and metastases underscores the importance of comprehensive multidisciplinary therapeutic *** randomized clinical trials have been performed;however,they have been challenged by the lack of active agents,a limited number of accrued patients,and a grouping of all patients together regardless of where in the biliary tract the tumor *** has resulted in variations in treatment strategies and multiple treatment options that range from immunotherapy to radiation to hepatic artery infusion therapy(more on this later).A greater understanding of the mutational landscape of biliary tract cancers has resulted in optimism around appropriately targeted agents and combination ***,many of these regimens await robust outcomes data,and it is questionable if they significantly move the needle forward to improve overall *** now,more than ever,there is a need for updated treatment guidelines.

关键词： Gallbladder cancer cholangiocarcinoma guidelines bile duct cancer hepatic artery infusion pump

Cancer and Covid-19 in the Department of Internal Medicine and medical oncology at the National Teaching Hospital Hubert Koutoukou Maga of Cotonou, about 4 Cases: A Review of the Literature

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Open Journal of Internal Medicine 2021年第4期11卷 298-309页

作者： Azon Kouanou Angèle Agbodandé Kouessi Anthelme Sokadjo Yves Morel Missiho Mahoutin Semassa Ghislain Faladé Adélakoun Ange Géoffroy Murhula Katabana Delphin Kouanou Olamidé Marlene Marie Dénise Ahoussoussi Cornelly Tokpanoudé Elodie Zannou Djimon Marcel Internal Medicine-medical oncology Unity of the National Teaching Hospital Center (NTHC)-Hubert Kougougou Maga (HKM) of Cotonou Cotonou Benin Internal Medicine Department University Clinics Bukavu (U.O.B) Democratic Republic of the Congo

Coronavirus Disease-19 (COVID-19) manifests itself by a respiratory attack that can go from mild to severe forms. The factors favoring the severe forms are age, arterial hypertension, diabetes mellitus, and cancer. We report 4 cases of COVID-19 on cancer, followed in the Department of Internal Medicine and medical oncology of National Teaching Hospital Center Hubert Kougougou Maga (NTHC-HKM). Case 1: A hypertensive 65-year-old female patient with a severe form of COVID-19 on an FIGO (International Federation of Gynecology and Obstetrics) IVB endometrioid adenocarcinoma with pulmonary metastasis: unfavorable evolution under treatment with death. Case 2: A 56-year-old hypertensive patient with severe COVID-19 with pulmonary metastatic recurrence of SBRIII, HER2 positive invasive ductal carcinoma of the left breast: favorable evolution with cure of COVID-19, subsequent death related to active tumor. Case 3: A 37-year-old patient with a moderate form of COVID-19 with hepatocellular carcinoma complicating post alcoholic cirrhosis, CHILD C: favorable evolution with cure of COVID-19, patient lost to follow-up. Case 4: A 56-year-old patient, hypertensive, type II diabetic, presenting a severe form of COVID-19 on a field of ovarian serous adenocarcinoma of high grade FIGO IV A with pleuropulmonary metastasis: favorable evolution with cure of COVID-19, subsequent stroke, patient followed in palliative home hospitalization. The diagnosis of COVID-19 in cancer with pulmonary metastases is difficult. The pulmonary location of tumors seems to be a factor favoring severe forms.

关键词： COVID-19 Cancer NTHC-HKM

Levels of evidence and grades of recommendation supporting European society for medical oncology clinical practice guidelines

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

oncology Research 2024年第5期32卷 807-815页

作者： MARKO SKELIN BRUNA PERKOV-STIPIČIN SANJA VUŠKOVIĆ MARINAŠANDRK PLEHAČEK ANE BAŠIĆ DAVIDŠARČEVIĆ MAJA ILIĆ IVAN KREČAK Pharmacy Department General Hospital ofŠibenik-Knin CountyŠibenikCroatia Faculty of Medicine University of RijekaRijekaCroatia Undergraduate Study in Nursing University of Applied SciencesŠibenikCroatia Department of oncology University Hospital Center ZagrebZagrebCroatia Pharmacies Joukhadar Sveta NedeljaCroatia Pharmacies Prima Pharme ZagrebCroatia Pharmacy Department General Hospital ZadarZadarCroatia Pharmacy Department General Hospital PulaPulaCroatia Department of Internal Medicine General Hospital ofŠibenik-Knin CountyŠibenikCroatia

Background:The European Society for medical oncology(ESMO)guidelines are among the most comprehensive and widely used clinical practice guidelines(CPGs)***,the level of scientific evidence supporting ESMO CPG recommendations has not been systematically *** study assessed ESMO CPG levels of evidence(LOE)and grades of recommendations(GOR),as well as their trends over time across various cancer ***:We manually extracted every recommendation with the Infectious Diseases Society of America(IDSA)classification from each *** examined the distribution of LOE and GOR in all available ESMO CPG guidelines across different topics and cancer ***:Among the 1,823 recommendations in the current CPG,30%were classified as LOEⅠ,and 43%were classified as GOR ***,there was a slight decrease in LOEⅠ(−2%)and an increase in the proportion of GOR A(+1%)in the current CPG compared to previous *** proportion of GOR A recommendations based on higher levels of evidence such as randomized trials(LOEⅠ–Ⅱ)shows a decrease(71%vs.63%,p=0.009)while recommendations based on lower levels of evidence(LOEⅢ–Ⅴ)show an increase(29%vs.37%,p=0.01)between previous and current *** the current versions,the highest proportion of LOEⅠ(42%)was found in recommendations related to pharmacotherapy,while the highest proportion of GOR A recommendations was found in the areas of pathology(50%)and diagnostic(50%)*** variability in LOEⅠand GOR A recommendations and their changes over time was observed across different cancer ***:One-third of the current ESMO CPG recommendations are supported by the highest level of *** well-designed randomized clinical trials are needed to increase the proportion of LOEⅠand GOR A recommendations,ultimately leading to improved outcomes for cancer patients.

关键词： ESMO guidelines Clinical practice guidelines Level of evidence Grade of recommendation